HRMY as reported
Harmony Biosciences Holdings, Inc. reported $899M of revenue over the trailing twelve months, +21% on the year before. 11 reported series are charted on this page, each one as filed.
$899M
Revenue, trailing twelve months · to Q1 2026 · +21% against the twelve months before
- Net Income
- $146M
Net Income · −4.7% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $348M
Free Cash Flow · trailing twelve months to Q4 2025
- Op Margin
- 21%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $899M | +21% | Q1 2026 |
| Net Income | $146M | −4.7% | Q1 2026 |
| EPS | $2.49 | −5.0% | Q1 2026 |
| Gross Margin | 77% | n/a | Q1 2026 |
| Op Margin | 21% | n/a | Q1 2026 |
| Net Margin | 16% | n/a | Q1 2026 |
| ROE | 20% | n/a | Q1 2026 |
| ROA | 14% | n/a | Q1 2026 |
| ROIC | 50% | n/a | Q1 2026 |
| Free Cash Flow | $348M | n/a | Q4 2025 |
| P/E | 15.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Harmony Biosciences Holdings, Inc. (HRMY) - Revenue & ProfitRevenue & ProfitHarmony Biosciences Holdings, Inc. (HRMY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com